['rheumatoid arthritis (ra)']
['placebo', 'niclosamide', 'etanercept']

        Inclusion Criteria:

          -  Patients with RA, as defined by the American College of Rheumatology (ACR) 1987
             revised criteria or ACR/EULAR 2010,

          -  Severly Active RA by calculating either DAS28 or SDAI or CDAI.

          -  Patient selected are those who started etanercept for less than 3months and still
             active.

        Exclusion Criteria:

          -  Patients on nonsteroidal anti-inflammatory drugs (NSAID) 2 days before entry into this
             study. or methotrexate (MTX)..

          -  Patients with hypersensitivity or severe adverse effects to niclosamide .

          -  Renal impairment.

          -  Hepatic impairment.

          -  Pregnancy or a desire to become pregnant.

          -  Breast feeding.

          -  Patients with Juvenile RA [16 years old or younger].

          -  Patients using other conventional disease modifying antirheumatic drugs (DMARDs).

          -  Patients on steroid.

          -  Patients with coexistence other connective tissue diseases or hypothyroid disease.

          -  Patient with mild or inactive RA.
      